2 results found
Biotech startup InduPro has secured $77 million in Series B funding and commenced its first human clinical trial for lead cancer drug IDP-001. The company's novel proximity-guided platform aims to precisely target tumors by identifying specific protein combinations on cancer cell surfaces, sparing healthy tissue. This milestone, alongside a significant Eli Lilly partnership, marks a pivotal step for the Seattle and Cambridge-based firm.
Eli Lilly is set to acquire Seattle-area biotech Curevo Vaccine for up to $1.5 billion to bolster its infectious disease portfolio. The deal centers on Curevo's Phase 3-ready shingles vaccine candidate, amezosvatein, which demonstrated a more than 50% reduction in side effects during Phase 2 studies, aiming to boost vaccination rates among older adults.
